Anya Biopharm Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	16.27	21.6	2.32	2.5
Revenue Growth (YoY)	-24.66%	831.26%	-7.09%	-
Cost of Revenue	0.14	0.14	0.09	0.09
Gross Profit	16.13	21.46	2.23	2.41
Selling, General & Admin	26.54	33.56	10.81	8.54
Research & Development	47.93	30.75	20.03	32.67
Operating Expenses	74.47	64.31	30.85	41.21
Operating Income	-58.33	-42.85	-28.62	-38.8
Interest Expense	-0.52	-0.34	-0.02	-0.02
Interest & Investment Income	15.87	5.21	0.02	0
Currency Exchange Gain (Loss)	-20.35	3.27	0.54	-2.96
Other Non Operating Income (Expenses)	0.01	0	0.03	-0
Pretax Income	-63.32	-34.72	-28.05	-41.78
Income Tax Expense	0.69	2.13	0.03	0.04
Earnings From Continuing Operations	-64.01	-36.84	-28.08	-41.82
Minority Interest in Earnings	-0.01	-0.12	0	-0.01
Net Income	-64.02	-36.96	-28.08	-41.83
Net Income to Common	-64.02	-36.96	-28.08	-41.83
Shares Outstanding (Basic)	49	33	2	2
Shares Outstanding (Diluted)	49	33	2	2
Shares Change (YoY)	48.38%	1351.36%	-	-
EPS (Basic)	-1.30	-1.12	-12.32	-18.35
EPS (Diluted)	-1.30	-1.12	-12.32	-18.35
Free Cash Flow	-70.81	-30.17	-24.2	-44.16
Free Cash Flow Per Share	-1.44	-0.91	-10.61	-19.37
Gross Margin	99.14%	99.36%	96.16%	96.55%
Operating Margin	-358.51%	-198.43%	-1233.98%	-1554.37%
Profit Margin	-393.47%	-171.14%	-1210.82%	-1675.92%
Free Cash Flow Margin	-435.16%	-139.69%	-1043.60%	-1769.15%
EBITDA	-56.83	-42.17	-28.19	-38.66
EBITDA Margin	-	-195.25%	-	-
D&A For EBITDA	1.51	0.69	0.42	0.14
EBIT	-58.33	-42.85	-28.62	-38.8
EBIT Margin	-	-198.43%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.